



Published in final edited form as:

*Phytochem Lett.* 2008 August 21; 1(2): 89–93. doi:10.1016/j.phytol.2008.03.003.

## Constituents of *Nelumbo nucifera* leaves and their antimalarial and antifungal activity

Vijai K. Agnihotri<sup>a</sup>, Hala N. ElSohly<sup>a</sup>, Shabana I. Khan<sup>a</sup>, Melissa R. Jacob<sup>a</sup>, Vaishali C. Joshi<sup>a</sup>, Troy Smillie<sup>a</sup>, Ikhlas A. Khan<sup>a,b,\*</sup>, and Larry A. Walker<sup>a</sup>

<sup>a</sup>National Center for Natural Products Research, Research Institute of Pharmaceutical Sciences, School of Pharmacy, The University of Mississippi, University, MS 38677, USA

<sup>b</sup>Department of Pharmacognosy, School of Pharmacy, The University of Mississippi, University, MS 38677, USA

### Abstract

From the leaves of *Nelumbo nucifera* (an aquatic plant), one new compound, 24(*R*)-ethylcholest-6-ene-5 $\alpha$ -ol-3-*O*- $\beta$ -D-glucopyranoside (**1**), along with 11 known metabolites (**2–12**), were isolated and identified by spectroscopic methods including 1D- and 2D NMR. Antifungal activity for (*R*)-roemerine (**3**) (IC<sub>50</sub>/MIC = 4.5/10  $\mu$ g/mL against *Candida albicans*) and antimalarial activity for (*R*)-roemerine (**3**) and *N*-methylasimilobine (**5**) (IC<sub>50</sub> = 0.2 and 4.8  $\mu$ g/mL for the D6 clone, respectively, and 0.4 and 4.8  $\mu$ g/mL for the W2 clone, respectively) was observed. None of the compounds were cytotoxic to Vero cells up to a concentration of 23.8  $\mu$ g/mL. NMR data for 10-icosanol (**7**) and 7,11,15-trimethyl-2-hexadecanone (**10**) are presented for the first time. An analysis of the structure–activity relationship shows that the substituents in position C-1 and C-2 of aporphine alkaloids are crucial for the antimalarial activity.

### Keywords

*Nelumbo nucifera*; Nelumbonaceae; 24(*R*)-Ethylcholest-6-ene-5 $\alpha$ -ol-3-*O*- $\beta$ -D-glucopyranoside; Roemerine; Antimalarial; SAR

## 1. Introduction

*Nelumbo nucifera* Gaertn. (Nelumbonaceae), commonly known as lotus, is a perennial aquatic plant grown and consumed throughout Asia. All parts of *N. nucifera* have been used for various medicinal purposes in oriental medicine. Lotus is reported to possess antidiarrheal, psychopharmacological, diuretic, antipyretic, antimicrobial and hypoglycemic activities (Rai, Wahile, Mukherjee, Saha, & Mukherjee, 2006). Previous work on the leaves of this plant resulted in the isolation of several alkaloids and other constituents (Kashiwada et al., 2005; Wassel, Saeed, Ibrahim, & El-Eraqy, 1996). As part of our on going search for antimicrobial and antimalarial compounds from higher plants, we have undertaken an

\*Corresponding author at: National Center for Natural Products Research, Research Institute of Pharmaceutical Sciences, School of Pharmacy, The University of Mississippi, University, MS 38677, USA. Tel.: +1 662 915 7821; fax: +1 662 915 7989. ikhan@olemiss.edu (I.A. Khan).

investigation of the leaves of this plant. In this study, we describe the isolation, structure elucidation and biological activities of a new (**1**) and 11 (**2–12**) known compounds (Fig. 1) from the leaves of *N. nucifera* and some structure activity relationship (SAR) for the antimalarial activity of aporphine alkaloids.

## 2. Results and discussion

Compound **1** was isolated as a white solid. Its molecular formula of  $C_{35}H_{60}O_7$ , was determined by HRESIMS and indicated the presence of six degrees of unsaturation.  $^{13}C$  NMR and DEPT spectra showed 35 signals including 6 methyls, 11 methylenes, 15 methines and 3 quaternary carbons. Careful examination of the  $^1H$ -,  $^{13}C$  NMR and their 2D long-range correlations (Fig. 2) and comparison of aglycone values with literature indicated that compound **1** was a glycoside of the previously reported aglycone 24-ethyl-cholest-6-ene-3 $\beta$ ,5 $\alpha$ -diol (Greca, Fiorentino, Molinaro, Monaco, & Previtera, 1994). Cross-peak correlations for H-4 ( $\delta$  3.18) to C-2 ( $\delta$  30.3), C-3 (75.6) and with C-5 ( $\delta$  83.1) in the HMBC spectrum was used to place a further hydroxyl at the C-5 position and double bond protons present at  $\delta$  5.71 and 5.95 also showed HMBC correlations with C-5 ( $\delta$  83.1) indicating that there was a double bond between C-6 and C-7. The hydroxyl group at C-5 was determined to be  $\alpha$ -oriented (Holland & Jahangir, 1983) from the signals observed in the  $^{13}C$  NMR for C-6 ( $\delta$  = 133.9) and C-7 ( $\delta$  = 132.2). The absolute configuration at C-24 was determined to be *R* (Wright et al., 1978) on the basis of the comparison of  $^{13}C$  NMR of **1** ( $\delta_C$  = 46.4) and  $\beta$ -sitosterol-3-*O*- $\beta$ -D-glucopyranoside (**11**) ( $\delta_C$  = 46.4, having an *R* configuration at C-24) in pyridine-*d*<sub>5</sub>. The configuration of the anomeric carbon was defined as  $\beta$  from the coupling constant of 8.0 Hz. *In situ* acid hydrolysis of **1** afforded D-glucose. According to the molecular rotation formula (Klyne, 1950), the specific rotation of **1** ( $[\alpha]_D^{26}$ :  $-14^\circ$ ) was multiplied by its molecular wt (*m/z* 592), the resulting value ( $-8288$ ) was then divided by 100. The molecular rotation  $[M]_D^\alpha$  was found to be  $-82.9^\circ$  and is comparable with levorotatory Me- $\beta$ -D-glucopyranoside ( $[M]_D^\alpha$  =  $-66^\circ$ ) (Germonprez, Puyvelde, Maes, Tri, & Kimpe, 2004). According to the molecular rotation calculation, the glucose in **1** should possess the absolute configuration D-form, which is the common form for glucose existing in nature. The glycosidation position was unambiguously determined by a three-bond correlation between the glycosyl anomeric proton H-1' ( $\delta_H$  = 5.13) and C-3 ( $\delta_C$  = 75.6) using HMBC. On the basis of the above evidence, the structure of **1** was established as 24(*R*)-ethyl-cholest-6-ene-5 $\alpha$ -ol-3-*O*- $\beta$ -D-glucopyranoside, a new steroid glucoside.

Eleven known compounds were identified as, dehydroroemerine (**2**), (*R*)-roemerine (**3**), nuciferine (**4**), *N*-methylasimilobine (**5**), and anonaine (**6**) (Guinaudeau, Leboeuf, & Cave, 1975, 1983), 10-eicosanol (**7**), 3,7,11,15-tetramethyl-1-hexadecen-3-ol (isophytol) (**8**) (Ahmad & Ali, 1991), 3,7,11,15-tetramethyl-2-hexadecen-1-ol (*trans*-phytol) (**9**) (Sims & Pettus, 1976), 7,11,15-trimethyl-2-hexadecanone (**10**) (Worner & Schreier, 1991),  $\beta$ -sitosterol-3-*O*- $\beta$ -D-glucopyranoside (**11**) (Kojima, Sato, Hatano, & Ogura, 1990) and quercetin 3-*O*- $\beta$ -D-glucopyranoside (**12**) (Markham, Ternai, Stanley, Geiger, & Mabry, 1978), by comparison of their spectral data with published values. This is the first report for the spectral data of **7**, that was previously prepared synthetically (Churchward, Gibson, Meakins, & Mulley, 1950), and without any reference or spectral evidence isolated from

*Semiaquilegia adoxoides* (Feng et al., 2006). The hydroxyl group of compound **7** was confirmed at position 10 by the GC–MS fragmentation pattern. Compound **10** was previously reported in the volatile fraction of *Galium odoratum* (Worner & Schreier, 1991). This is the first report of the isolation of **10** from *N. nucifera* and the first report of its <sup>1</sup>H- and <sup>13</sup>C NMR data.

The crude ethanolic extract along with fractions A–D (see Section 3) and all purified compounds except **2** and **6** were evaluated for *in vitro* antimalarial activity (against chloroquine sensitive (D6) and resistant (W2) clones of *Plasmodium falciparum*), cytotoxicity and for antifungal activity. Fractions A, C, D and compounds **3** and **5** exhibited activity against D6 (IC<sub>50</sub> of 9.2, 3.6, 1.7, 0.2 and 4.8 µg/mL, respectively) and W2 clones (IC<sub>50</sub> of 3.5, 3.2, 4.5, 0.4 and 4.8 µg/mL, respectively). The selectivity index of the antimalarial activity versus toxicity for compound **3** was 122 and 62 for D6 and W2 clones, respectively, as compared to a selectivity index of 5 for both clones for compound **5**. Chloroquine and artemisinin were used as positive controls which showed IC<sub>50</sub> values of 16.0 and 8.5 ng/mL (for D6) and IC<sub>50</sub> of 150.0 and 9.0 ng/mL (for W2), respectively. None of the tested compounds or fractions had cytotoxic effects towards mammalian kidney fibroblasts (Vero cells) up to a concentration of 23.8 µg/mL. Only compound **3** had antifungal activity against *Candida albicans* with IC<sub>50</sub>/MIC values of 4.5/10 µg/mL, respectively. The positive control amphotericin B gave IC<sub>50</sub>/MIC values of 0.2/0.6 µg/mL, respectively. This is the first report of the antimalarial activity of **3**.

Compounds **3–5** have a similar aporphine alkaloid skeleton. The only difference is substitution at position C-1 and C-2. Compound **4** exhibited no activity and that the most potent metabolite (**3**) possessed a methylenedioxy moiety.

A literature survey for biological activity of **3** and **5** showed that **3** reverses a multidrug resistance phenotype and possessed weak cytotoxicity (You et al., 1995), mutagenicity (Nozaka et al., 1990), a relaxant effect (Chulia et al., 1995) and an inhibitory activity for CD45 protein tyrosine phosphatase (Miski et al., 1995), however **5** inhibited platelet aggregation (Chang, Wei, Teng, & Wu, 1998) and had a sedative effect (Han, Park, & Park, 1989).

### 3. Experimental

#### 3.1. General experimental procedures

Optical rotations were determined with an AUTOPOL IV polarimeter. IR spectra were recorded on a JASCO 302-A spectrometer. The 1D- and 2D NMR spectra were run on a Varian 400 Mercury plus NMR spectrometer. Multiplicity determination (DEPT) and 2D NMR spectra (COSY, HMQC, and HMBC) were performed with standard pulse programs. GC–MS analysis was conducted using a Hewlett–Packard 5890 Series II plus/5972 MSD system, using a DB-5 capillary column. Column temperature, 150 °C (5 min) to 240 °C at 7 °C/min., injector temperature 240 °C, detector temperature 250 °C; helium was used as the carrier gas (39.9 cm/s). The mass spectra were obtained using an Agilent Series 1100 SL HPLC connected to a time of flight mass detector (model G1969A, Agilent Technologies)

equipped with an ESI interface. Column chromatography was run using silica gel (40  $\mu$ m, J.T. Baker), RP-18 (40  $\mu$ m Bakerbond, J.T. Baker) and alumina (150 mesh, Sigma–Aldrich).

### 3.2. Plant material

The leaves of *N. nucifera* were purchased in 2004 from [www.plumflowers.com](http://www.plumflowers.com), and authenticated in-house by Dr. Vaishali C. Joshi (taxonomist). A voucher specimen is deposited in the plant repository at The National Center for Natural Products Research, University of Mississippi (Voucher # NENUN 2449).

### 3.3. Extraction and isolation

The dried powdered material (700 g) was percolated with 95% EtOH (15 L). The ethanol extract was evaporated to dryness (75.44 g, 10.8%). Part of the extract (38.47 g) was fractionated using a published procedure (Kupchan, Dasgupta, Fujita, & King, 1963) to yield an alkaloidal fraction (0.54 g, fraction A) and a neutral/acidic fraction (20.0 g, fraction B). Part of fraction A (0.34 g) was separated into a phenolic alkaloidal fraction (0.14 g, fraction C) and a non-phenolic alkaloidal fraction (0.2 g, fraction D). Part of fraction D (0.14 g) was subjected to column chromatography using silica gel (13 g, 1 cm  $\times$  30 cm) eluted with a step gradient of petroleum ether/benzene and benzene/acetone to yield 14 fractions (D<sub>1</sub>–D<sub>14</sub>). Fraction D<sub>3</sub> eluted with petroleum ether/ benzene (6:4, 65 mL) afforded **2** (1.3 mg). Fractions D<sub>10</sub>, D<sub>11</sub>, D<sub>12</sub> and D<sub>14</sub> eluted with benzene/acetone (96:4, 100 mL), (94:6, 150 mL), (93:7, 140 mL) and (82:18, 154 mL), respectively, afforded **3** (7 mg), **4** (16 mg), **5** (6 mg) and **6** (1.2 mg), respectively. Chromatography of fraction C (134 mg) over an alumina column (20 g, 1 cm  $\times$  28 cm) using a step gradient solvent system consisting of benzene/acetone, yielded an additional amount of **5** (29 mg).

Column chromatography of fraction B (20.0 g) on a silica gel column (350 g, 6.5 cm  $\times$  40 cm) eluting with petroleum ether (1.2 L), CHCl<sub>3</sub> (2.0 L), CHCl<sub>3</sub>/EtOAc (1:1, 0.5 L), EtOAc (0.9 L), EtOAc/acetone (1:1, 0.6 L), and acetone (3.0 L) afforded four fractions: E–H (2.4, 11.2, 1.1, and 2.1 g, respectively). Column chromatography of fraction F (10.4 g) using silica gel (200 g, 3 cm  $\times$  60 cm) and eluting with a gradient solvent system consisting of hexane/CHCl<sub>3</sub> with increasing polarity yielded seven fractions: F<sub>1</sub>–F<sub>7</sub>. Fraction F<sub>2</sub> (1.5 g) was rechromatographed over a silica gel column (200 g, 3 cm  $\times$  60 cm) using hexane/EtOAc (98:2) to afford **10** (5 mg, 220 mL) and **7** (1 g, 1.4 L). Fractions F<sub>4</sub> (29 mg) and F<sub>6</sub> (15 mg) each containing one major spot, were purified on a silica gel column using hexane/EtOAc (99:1) to yield **8** (9 mg, 29 mL) and **9** (10 mg, 100 mL), respectively. Column chromatography of fraction G (1.1 g) using silica gel (80 g, 3 cm  $\times$  21 cm) and a step gradient solvent system consisting of CHCl<sub>3</sub>/EtOAc of increasing polarity, followed by EtOAc/MeOH mixtures, yielded 13 fractions (I<sub>1</sub>–I<sub>13</sub>). Fractions I<sub>10</sub> and I<sub>11</sub> were eluted with EtOAc/MeOH (99.5:0.5 and 99:1.0, 150 mL and 1 L, respectively) were pooled (80 mg). This residue was purified on a RP-18 column (18 g, 1 cm  $\times$  31 cm) eluting with MeOH to afford **1** (2.4 mg, 10 mL), and **11** (12 mg, 30 mL). Fractions I<sub>12</sub> and I<sub>13</sub>, eluted with EtOAc/MeOH (98:2, 250 mL and 97:3, 200 mL) were pooled to yield **12** (12 mg).

### 3.4. 24(R)-Ethylcholest-6-en-5- $\alpha$ -ol-3-O- $\beta$ -D-glucopyranoside (1)

White powder;  $[\alpha]_D^{26}$   $14^\circ$  (–) (c 0.1), pyridine; IR ( $\text{cm}^{-1}$ ): 3388 (–C–OH), 1591 (C=C) neat max;  $^1\text{H}$  NMR (pyridine- $d_5$ , 400 MHz,  $\delta$ ): 5.95 (1H, dd, 2.4, 9.6, H-7), 5.71 (1H, d, 11.2, H-6), 5.13 (1H, d, 8.0, H-1'), 4.87 (1H, m, H-3), 4.48 (1H, dd, 2.4, 11.6, 1H-6'), 4.40 (1H, dd, 4.8, 11.6, 1H-6'), 4.27 (1H, m, H-3'), 4.30 (1H, m, H-4'), 4.09 (1H, t, 8.4, H-2'), 3.86 (1H, m, H-5'), 3.18 (1H, dd, 12.8, 4.4, 1H-4), 2.30 (1H, m, 1H-2), 1.95 (3H, m, 1H-4, 1H-8, 1H-12), 1.85 (2H, m, 1H-2, 1H-16), 1.72 (1H, m, 1H-1), 1.68 (1H, m, 1H-25), 1.52 (1H, m, 1H-15), 1.40 (6H, m, 1H-1, 2H-11, 1H-16, 1H-20, 1H-22), 1.30 (3H, m, 1H-15, 2H-28), 1.24 (2H, m, 2H-23), 1.20 (1H, m, 1H-12), 1.15 (1H, m, 1H-14), 1.10 (1H, m, 1H-22), 1.06 (1H, m, 1H-17), 1.00 (2H, m, 1H-9, 1H-24), 1.02 (3H, d, 6.4, 3H-27), 0.96 (3H, d, 5.6, 3H-21), 0.94 (3H, s, 3H-19), 0.85 (3H, d, 6.4, 3H-26), 0.89 (3H, t, 6.8, 3H-29), 0.67 (3H, s, 3H-18);  $^{13}\text{C}$  NMR (pyridine- $d_5$ , 100 MHz,  $\delta$ ): 29.0 (C-1), 30.3 (C-2), 75.6 (C-3), 34.0 (C-4), 83.1 (C-5), 133.9 (C-6), 132.2 (C-7), 39.4 (C-8), 44.6 (C-9), 39.0 (C-10), 21.5 (C-11), 40.6 (C-12), 44.0 (C-13), 54.1 (C-14), 24.4 (C-15), 29.5 (C-16), 56.5 (C-17), 12.5 (C-18), 15.7 (C-19), 36.8 (C-20), 19.2 (C-21), 34.5 (C-22), 26.8 (C-23), 46.4 (C-24), 29.8 (C-25), 20.3 (C-26), 19.6 (C-27), 23.7 (C-28), 12.5 (C-29), 104.0 (C-1'), 75.8 (C-2'), 78.9 (C-3'), 72.0 (C-4'), 78.5 (C-5'), 63.1 (C-6'); HRESIMS (–),  $m/z$  627.4040  $[\text{M}+\text{Cl}]^-$  (calcd. for  $\text{C}_{35}\text{H}_{60}\text{O}_7\text{Cl}$ , 627.4027).

### 3.5. Acid hydrolysis of 1

Compound 1 and an authentic sugar sample (D-glucose) were spotted on a silica gel TLC plate and hydrolyzed *in situ* by exposure to HCl vapor at 70 °C for 25 min. The TLC plate was then developed with  $\text{CHCl}_3/\text{MeOH}/\text{AcOH}/\text{H}_2\text{O}$  (14:6:2:1) and sprayed with 0.5% vanillin in 5% ethanolic sulfuric acid for visualization. The hydrolyzed glucose moiety matched the  $R_f$  (0.28) of the standard D-glucose.

### 3.6. 10-Eicosanol (7)

White solid, optically inactive; IR ( $\text{cm}^{-1}$ ): 2849, 2916 (C–H), 3332 (–C–OH) neat max;  $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 400 MHz,  $\delta$ ): 0.85 (3H, d,  $J = 5.2$  Hz,  $\text{CH}_3$ -1 or  $\text{CH}_3$ -20), 0.86 (3H, d,  $J = 5.2$  Hz,  $\text{CH}_3$ -20 or  $\text{CH}_3$ -1), 1.23 (26H, brs, H-2-7 and 13–19), 1.34 (8H, brs, H-8, 9, 11, 12), 3.55 (1H, s, H-10);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 100 MHz,  $\delta$ ): 72.3 (C-10), 37.7 (C-9, 11), 32.1 (C-3, 18,  $\omega$ -2), 29.9 (C-5, 6, 7, 13, 14, 15, 16), 29.5 (C-4, 17,  $\omega$ -3), 25.9 (C-8, 12), 22.9 (C-2, 19,  $\omega$ -1), 14.4 (C-1, 20); GC, RT 56.0 min; GC/MS  $m/z$  297  $[\text{M}-\text{H}]^+$ , 157, 139, 125, 111, 97, 83, 69 and 55;  $m/z$  297  $[\text{M}-\text{H}]^+$  (calcd. for  $\text{C}_{20}\text{H}_{41}\text{O}$ , 297).

### 3.7. 7,11,15-Trimethyl-2-hexadecanone (10)

Colorless liquid, optically inactive; IR ( $\text{cm}^{-1}$ ) 2953, 2923, 2850 (C–H), 1719 ( $\text{C}=\text{O}$ ) neat max;  $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 400 MHz,  $\delta$ ) 2.37 (2H, t, 7.2, 2H-3), 2.10 (3H, s, 3H-1), 1.54 (2H, m, 2H-4), 1.48 (1H, m, 1H-15), 1.34 (2H, m, 1H-7, 1H-11), 1.22 (10H, m, 2H-5, 2H-8, 2H-9, 2H-10 and 2H-12), 1.01–1.14 (6H, m, 2H-6, 2H-13, 2H-14), 0.84 (6H, d, 6.4, 3H-15a, 3H-16), 0.82 (6H, d, 3H-7a, 3H-11a);  $^{13}\text{C}$  NMR (pyridine- $d_5$ , 100 MHz,  $\delta$ ): 30.1 (C-1), 209.6 (C-2), 44.4 (C-3), 21.6 (C-4), 29.9 (C-5), 36.7 (C-6), 32.9 and 33.0 (C-7 or C-11, values may interchanged), 19.8 (C-7a), 37.4, 37.5 and 37.6 (C-8, C-10, C-12, values may

interchanged), 24.6 (C-9), 20.0 (C-11a), 25.0 (C-13), 39.6 (C-14), 28.2 (C-15), and 22.9 (C-15a, C-16); ESI-MS  $m/z$  305  $[M+Na]^+$  (calcd. for  $C_{19}H_{38}ONa$ , 305).

### 3.8. Determination of in vitro antimalarial and cytotoxic activities

The *in vitro* antimalarial activity of test samples was determined against two strains of *P. falciparum* (D6: chloroquine-sensitive; W2: chloroquine-resistant). The assay was based on the determination of plasmodial LDH activity using Malstat™ reagent and was performed in 96-well plates as described previously (Jain et al., 2005). The level of *in vitro* cytotoxicity of each sample was also determined towards mammalian kidney fibroblasts (VERO cells) as described earlier (Jain et al., 2005) and the selectivity index (SI) was calculated as the ratio of  $IC_{50}$  in Vero cells and  $IC_{50}$  in *P. falciparum*. Two standard antimalarial agents chloroquine and artemisinin were used as positive controls and DMSO was used as a vehicle control.

### 3.9. Determination of antifungal activity

Susceptibility testing was performed using a modified version of the CLSI (formerly NCCLS) methods (NCCLS, 2002; Jain et al., 2005). *C. albicans* ATCC 90028 was obtained from the American Type Culture Collection (Manassas, VA). Amphotericin B (ICN Biomedicals, Ohio) was included as a positive control. The MIC was defined as the lowest test concentration that allows no detectable growth.


## Acknowledgments

The authors thank Dr. Bharathi Avula for providing mass spectroscopic data, Frank T. Wiggers, Dr. Zulfiqar Ali and Dr. Rahul S. Pawar for NMR data and Ms Marsha Wright for conducting the antimicrobial testing, which was supported by NIH, NIAID Division of AIDS, Grant no. AI 27094. This work was supported in part by the United States Department of Agriculture, Agricultural Research Service, Specific Cooperative Agreement no. 58-6408-2-0009 and Grant number P20RR021929 from the National Center for Research Resources.

## References


- Ahmad VU, Ali MS. Terpenoids from marine red alga *Laurencia pinnatifida*. *Phytochemistry*. 1991; 30:4172–4174.
- Chang F, Wei J, Teng C, Wu Y. Two new 7-dehydroaporphine alkaloids and antiplatelet action aporphines from the leaves of *Annona purpurea*. *Phytochemistry*. 1998; 49:2015–2018. [PubMed: 9883592]
- Chulia S, Ivorra MD, Cave A, Cortes D, Noguera MA, D'Ocon MP. Relaxant activity of three aporphine alkaloids from *Annona cherimolia* on isolated aorta of rat. *Journal of Pharmacy and Pharmacology*. 1995; 47:647–650. [PubMed: 8583365]
- Churchward VR, Gibson NA, Meakins RJ, Mulley JW. The preparation of a series of ( $\pm$ )-*n*-eicosanols and *n*-eicosanones. *Journal of Chemical Society*. 1950:959–960.
- Feng N, Zheng C, Hai-Tao C, Yong J, Fa-Kui C, Peng-Fei T. Constituents from the roots of *Semiaquilegia adoxoides*. *Chinese Journal of Chemistry*. 2006; 24:1788–1791.
- Germonprez N, Puyvelde LV, Maes L, Tri MV, Kimpe ND. New pentacyclic triterpene saponins with strong *anti-leishmanial* activity from the leaves of *Maesa balasae*. *Tetrahedron*. 2004; 60:219–228.
- Greca MD, Fiorentino A, Molinaro A, Monaco P, Previtera L. Hydroperoxysterols in *Arum italicum*. *Natural Product Letters*. 1994; 5:7–14.
- Guinaudeau H, Leboeuf M, Cave A. Aporphine alkaloids. *Lloydia*. 1975; 38:275–338. [PubMed: 241890]
- Guinaudeau H, Leboeuf M, Cave A. Aporphinoid alkaloids III. *Journal of Natural Products*. 1983; 46:761–835.

- Han BH, Park MH, Park JH. Chemical and pharmacological studies on sedative cyclopeptide alkaloids in some Rhamnaceae plants. *Pure and Applied Chemistry*. 1989; 61:443–448.
- Holland HL, Jahangir. Reactions of steroidal 4,5- and 5,6-epoxides with strong bases. *Canadian Journal of Chemistry*. 1983; 61:2165–2170.
- Jain M, Khan SI, Tekwani BL, Jacob MR, Singh S, Singh PP, et al. Synthesis, antimalarial, antileishmanial, and antimicrobial activities of some 8-quinolinamine analogues. *Bioorganic & Medical Chemistry*. 2005; 13:4458–4466.
- Kashiwada Y, Aoshima A, Ikeshiro Y, Chen Y, Furukawa H, Itoigawa M, et al. Anti-HIV benzyloquinoline alkaloids and flavonoids from the leaves of *Nelumbo nucifera*, and structure–activity correlations with related alkaloids. *Bioorganic & Medical Chemistry*. 2005; 13:443–448.
- Klyne W. The configuration of the anomeric carbon atoms in some cardiac glycosides. *Journal of Biochemistry*. 1950; 47:xli–xlii.
- Kojima H, Sato N, Hatano A, Ogura H. Sterol glucosides from *Prunella vulgaris*. *Phytochemistry*. 1990; 29:2351–2355.
- Kupchan SM, Dasgupta B, Fujita E, King ML. The alkaloids of American lotus, *Nelumbo lutea*. *Tetrahedron*. 1963; 19:227–232.
- Markham KR, Ternai B, Stanley R, Geiger H, Mabry TJ. Carbon-13 NMR studies of flavonoids-III. *Tetrahedron*. 1978; 34:1389–1397.
- Miski M, Shen X, Cooper R, Gillum AM, Fisher DK, Miller RW, et al. Aporphine alkaloids, CD45 protein tyrosine phosphatase inhibitors, from *Rollinia ulei*. *Bioorganic & Medicinal Chemistry Letters*. 1995; 5:1519–1522.
- NCCLS. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard M27-A2. Vol. 22. Villanova, PA: National Committee on Clinical Laboratory Standards; 2002.
- Nozaka T, Watanabe F, Tadaki S, Ishino M, Morimoto I, Kunitomo J, et al. Mutagenicity of isoquinoline alkaloids, especially of the aporphine type. *Mutation Research, Genetic Toxicology Testing*. 1990; 240:267–279.
- Rai S, Wahile A, Mukherjee K, Saha BP, Mukherjee PK. Anti-oxidant activity of *Nelumbo nucifera* (sacred lotus) seeds. *Journal of Ethnopharmacology*. 2006; 104:322–327. [PubMed: 16239089]
- Sims JJ, Pettus JA Jr. Isolation of free *cis*- and *trans*-phytol from the red alga *Gracilaria andersoniana*. *Phytochemistry*. 1976; 15:1076–1077.
- Wassel G, Saeed A, Ibrahim N, El-Eraqy W. Flavonoids of *Nelumbo nucifera* Gaertn and biological evaluation. *Egyptian Journal of Pharmaceutical Science*. 1996; 37:585–596.
- Worner M, Schreier P. Über die Aromastoff-Zusammensetzung von Waldmeister (*Galium odoratum* L. Scop). *Zeitschrift für Lebensmittel-Untersuchung und-Forschung*. 1991; 193:317–320.
- Wright JLC, McInnes AG, Shimizu S, Smith DG, Walter JA, Idler D, et al. Identification of C-24 alkyl epimers of marine sterols by <sup>13</sup>C nuclear magnetic resonance spectroscopy. *Canadian Journal of Chemistry*. 1978; 56:1898–1903.
- You M, Wickramaratne DBM, Silva GL, Chai H, Chagwedera TE, Farnsworth NR, et al. (–)-Roemerine, an aporphine alkaloid from *Annona senegalensis* that reverses the multidrug-resistance phenotype with cultured cells. *Journal of Natural Products*. 1995; 58:598–604. [PubMed: 7623038]



**Fig. 1.**  
Structures of some constituents of *Nelumbo nucifera*.





**Fig. 2.**  
Key HMBC correlations for compound **1**.